CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.
IPO Year: 2019
Exchange: NASDAQ
Website: cnspharma.com
10-Q - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
424B4 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
EFFECT - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
S-1/A - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
10-K/A - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
S-1 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
10-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
424B5 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
Brookline Capital initiated coverage of CNS Pharmaceuticals with a rating of Buy and set a new price target of $10.00